Tag: esketamine market growth

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Esketamine Market Growth Potential: How Will Market Size Shift Through 2030?

The esketamine market has seen substantial growth in recent years. The market is forecast to expand from $1.51 billion in 2025 to $1.67 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.8%. Historically, this growth can be attributed to unmet needs in major depressive disorder, limitations of traditional antidepressants, regulatory approvals for nasal esketamine, rising mental health awareness, and the expansion of specialty psychiatric clinics.

The esketamine market is anticipated to experience significant expansion in the coming years. Its valuation is projected to reach $2.5 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.6%. This expansion during the projection period stems from factors such as the rising incidence of treatment-resistant depression, a need for swift-acting treatments, the broader adoption of supervised outpatient delivery, an expanding mental health infrastructure, and ongoing investment in clinical research. Key developments anticipated within this timeframe involve the increasing uptake for treatment-resistant depression, the wider availability of nasal spray administration, greater utilization in acute psychiatric care environments, enhanced monitoring and regulated distribution, and intensified research efforts into rapid-acting antidepressants.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=96700594&type=smp&name=Esketamine%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Esketamine Market Industry Drivers: What’s Behind The Revenue Growth?

The anticipated expansion of the esketamine market over the next few years is largely attributed to the growing occurrence of treatment-resistant depression (TRD). TRD is defined as a form of depression that fails to respond even after trials of at least two distinct antidepressant drugs administered in appropriate dosages for an adequate period. The rise in TRD cases stems from the inadequate effectiveness of traditional antidepressants, resulting in extended and recurring depressive states. Esketamine offers assistance for TRD by utilizing a rapid-onset mechanism that targets NMDA receptors, thereby providing relief to individuals unresponsive to conventional antidepressant therapies. For instance, in September 2023, the National Institute of Mental Health (NIMH), a US-based federal agency, reported that, in 2023, approximately 30% of individuals with major depressive disorder in the U.S. were resistant to standard treatments. Consequently, the escalating occurrence of treatment-resistant depression is serving as a key driver for the growth of the esketamine market.

Esketamine Market Segment Landscape And Growth Outlook

The esketamine market covered in this report is segmented –

1) By Formulation Type: Nasal Spray, Injectable Form

2) By Indication: Treatment-Resistant Depression (TRD), Major Depressive Disorder with Suicidal Ideation or Behavior

3) By Patient Type: Adult Patients

4) By Treatment Setting: Hospital-Based Administration, Certified Specialty Clinics

5) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies

Subsegments:

1) By Nasal Spray: Single-Agent Esketamine Nasal Spray, Esketamine + Oral Antidepressant Combination Therapy

2) By Injectable Form: Intravenous (IV) Esketamine, Intramuscular (IM) Esketamine

#Esketamine Market Growth Trends: What’s Shaping The Future Outlook?

Leading companies within the esketamine market are focusing on developing advanced treatment solutions like monotherapy, aiming to improve depressive symptom relief beyond placebo effects. Monotherapy refers to managing a disease or medical condition using a single drug or treatment, rather than multiple combined therapies. For instance, in January 2025, US-based pharmaceutical company Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved SPRAVATO (esketamine) as the first and only monotherapy for adults with treatment-resistant depression (TRD). Clinical trials supported this approval, demonstrating SPRAVATO’s rapid ability to alleviate depressive symptoms, with significant improvements observed within 24 hours. This breakthrough offers a crucial option for approximately 30% of individuals unresponsive to traditional antidepressants, removing the need for concurrent oral medications. Although SPRAVATO has a favorable safety profile, it is administered under a Risk Evaluation and Mitigation Strategy (REMS) to address potential side effects. This achievement represents a significant advancement in TRD treatment, providing renewed hope for better patient outcomes.

Esketamine Market Competitive Landscape: Who Leads The Industry?

Major companies operating in the esketamine market are Johnson & Johnson, Janssen Pharmaceuticals, Sage Therapeutics Inc., VistaGen Therapeutics Inc., Cerecor Inc., Celon Pharma S.A., Hikma Pharmaceuticals plc, Seqens Group, Arevipharma GmbH, Nortec Química S.A., Supriya Lifescience Ltd., Maithri Drugs Pvt. Ltd., SynZeal Research Pvt. Ltd., XWPharma Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Aurobindo Pharma Ltd., H. Lundbeck A/S, Otsuka Pharmaceutical Co. Ltd.

View The Full Esketamine Market Report:

https://thebusinessresearchcompany.com/report/esketamine-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Esketamine Market Geographic Landscape: Which Region Dominates Industry Growth?

North America was the largest region in the esketamine market in 2025. The regions covered in the esketamine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Esketamine Market Expansion From $1.66 Billion In 2026 To $2.49 Billion In 2030

The esketamine market has undergone rapid expansion over the last several years. Its value is projected to increase from $1.51 billion in 2025 to $1.67 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.8%. The historical growth is largely explained by factors such as the significant unmet demands in treating major depressive disorder, the well-documented shortcomings of conventional antidepressant therapies, the regulatory endorsement of intranasal esketamine, a growing societal focus on mental health issues, and the proliferation of specialized psychiatric care facilities.

The esketamine market is projected to experience swift expansion over the coming years. By 2030, its value is anticipated to reach $2.5 billion, driven by a compound annual growth rate (CAGR) of 10.6%. This forecasted growth is fueled by factors such as the rising incidence of treatment-resistant depression, a growing need for therapies that work quickly, the expansion of supervised outpatient treatment programs, enhanced mental health infrastructure, and sustained investment in clinical research. Key developments shaping the market during this period include a broader uptake of esketamine for treatment-resistant depression, wider use of nasal spray delivery methods, increasing application in acute psychiatric care settings, stricter monitoring and controlled distribution practices, and ongoing research into rapid-acting antidepressant options.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Esketamine Market Opportunity Drivers: What Is Creating New Revenue Potential?

The growing number of cases of treatment-resistant depression (TRD) is anticipated to accelerate the expansion of the esketamine market in the foreseeable future. This condition is defined as depression that fails to respond after at least two separate trials of antidepressant medications, each taken at an adequate dosage and for a sufficient period. The rise in treatment-resistant depression stems from the limited effectiveness of conventional antidepressants, resulting in prolonged and recurring depressive episodes. Esketamine addresses TRD through its rapid-acting mechanism, which specifically targets NMDA receptors, providing relief for individuals who do not benefit from standard antidepressant therapies. A notable illustration comes from September 2023, when the National Institute of Mental Health (NIMH), a federal entity based in the United States, reported that approximately 30% of Americans diagnosed with major depressive disorder in 2023 exhibit resistance to conventional treatments. Consequently, the increasing frequency of treatment-resistant depression is fueling the upward trajectory of the esketamine market.

Esketamine Market Segment Performance And Strategic Opportunities

The esketamine market covered in this report is segmented –

1) By Formulation Type: Nasal Spray, Injectable Form

2) By Indication: Treatment-Resistant Depression (TRD), Major Depressive Disorder with Suicidal Ideation or Behavior

3) By Patient Type: Adult Patients

4) By Treatment Setting: Hospital-Based Administration, Certified Specialty Clinics

5) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies

Subsegments:

1) By Nasal Spray: Single-Agent Esketamine Nasal Spray, Esketamine + Oral Antidepressant Combination Therapy

2) By Injectable Form: Intravenous (IV) Esketamine, Intramuscular (IM) Esketamine

Esketamine Market Innovation Trends Driving Future Development

Key players in the esketamine market are prioritizing the creation of cutting-edge therapeutic approaches, particularly monotherapy, to achieve superior relief from depressive symptoms compared to a placebo. Monotherapy involves managing a medical condition with a single drug or treatment, avoiding the use of multiple combined therapies. For example, Johnson & Johnson, a pharmaceutical firm based in the U.S., announced in January 2025 that the FDA had approved SPRAVATO (esketamine) as the first standalone monotherapy for adults facing treatment-resistant depression (TRD). Clinical trial results supported this approval, showing that SPRAVATO could rapidly reduce depressive symptoms, with notable improvements appearing within 24 hours. This innovation offers a vital alternative for roughly 30% of patients who fail to benefit from conventional antidepressants, removing the requirement for additional oral medications. Although SPRAVATO presents a favorable safety profile, its administration is governed by a Risk Evaluation and Mitigation Strategy (REMS) to manage possible adverse effects. This achievement represents a substantial step forward in TRD management, providing renewed optimism for enhanced patient outcomes.

Esketamine Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the esketamine market are Johnson & Johnson, Janssen Pharmaceuticals, Sage Therapeutics Inc., VistaGen Therapeutics Inc., Cerecor Inc., Celon Pharma S.A., Hikma Pharmaceuticals plc, Seqens Group, Arevipharma GmbH, Nortec Química S.A., Supriya Lifescience Ltd., Maithri Drugs Pvt. Ltd., SynZeal Research Pvt. Ltd., XWPharma Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Aurobindo Pharma Ltd., H. Lundbeck A/S, Otsuka Pharmaceutical Co. Ltd.

Access The Complete Esketamine Market Report:

https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Esketamine Market Geographic Distribution And Regional Opportunities

North America was the largest region in the esketamine market in 2025. The regions covered in the esketamine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Are The Forecasted Market Size Figures For The Esketamine Market In 2026 And 2030?

The esketamine market has experienced significant expansion in recent years. It is anticipated to increase from $1.51 billion in 2025 to $1.67 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.8%. The growth observed in the past can be attributed to several factors, including unmet needs in major depressive disorder, the inherent limitations of traditional antidepressants, regulatory approvals granted for nasal esketamine, a heightened awareness of mental health, and the expansion of specialty psychiatric clinics.

The esketamine market size is projected for substantial expansion in the coming years. It will grow to $2.5 billion in 2030 at a compound annual growth rate (CAGR) of 10.6%. This anticipated growth during the forecast period stems from factors such as the rising incidence of treatment-resistant depression, the need for quick-acting treatments, the broader availability of supervised outpatient administration, the development of mental health infrastructure, and ongoing investment in clinical research. Key developments expected during this period involve the increasing use for treatment-resistant depression, the wider application of nasal spray administration, a rise in its deployment within acute psychiatric care settings, enhanced oversight and regulated supply, and continuous exploration into rapidly effective antidepressants.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp

What Important Drivers Are Powering The Esketamine Market Growth?

The anticipated expansion of the esketamine market in upcoming years is linked to the growing occurrence of treatment-resistant depression (TRD). TRD is defined as depression that fails to improve even after individuals have undergone at least two distinct antidepressant treatments, administered correctly and for an adequate period. The rise in TRD cases stems from the inadequate effectiveness of traditional antidepressants, which often results in enduring and recurring bouts of depression. Esketamine addresses TRD through a rapid-onset mechanism that targets NMDA receptors, providing a viable treatment option for those unaffected by standard antidepressant therapies. For example, the National Institute of Mental Health (NIMH), a federal agency located in the U.S., stated in September 2023 that approximately 30% of major depressive disorder patients in the U.S. showed resistance to conventional treatments in 2023. Consequently, the escalating frequency of treatment-resistant depression is a key factor propelling the expansion of the esketamine market.

Which Segment Groups Define The Esketamine Market Landscape?

The esketamine market covered in this report is segmented –

1) By Formulation Type: Nasal Spray, Injectable Form

2) By Indication: Treatment-Resistant Depression (TRD), Major Depressive Disorder with Suicidal Ideation or Behavior

3) By Patient Type: Adult Patients

4) By Treatment Setting: Hospital-Based Administration, Certified Specialty Clinics

5) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies

Subsegments:

1) By Nasal Spray: Single-Agent Esketamine Nasal Spray, Esketamine + Oral Antidepressant Combination Therapy

2) By Injectable Form: Intravenous (IV) Esketamine, Intramuscular (IM) Esketamine

What Trends Are Affecting The Growth Of The Esketamine Market?

Major companies operating in the esketamine market are concentrating on developing advanced treatment solutions, such as monotherapy, to enhance depressive symptom relief beyond what a placebo offers. Monotherapy refers to the use of a single drug or treatment to manage a disease or medical condition, rather than combining multiple therapies. For instance, in January 2025, Johnson & Johnson, a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved SPRAVATO (esketamine) as the first and only monotherapy for adults with treatment-resistant depression (TRD). Supported by clinical trials, the approval demonstrated that SPRAVATO could rapidly alleviate depressive symptoms, with significant improvements observed within 24 hours. This breakthrough provides a critical option for approximately 30% of individuals who do not respond to traditional antidepressants, eliminating the need for concurrent oral medications. While SPRAVATO has a favorable safety profile, it is administered under a Risk Evaluation and Mitigation Strategy (REMS) to address potential side effects. This milestone marks a significant advancement in TRD treatment, offering renewed hope for improved patient outcomes.

Which Firms Are Competing In The Esketamine Market?

Major companies operating in the esketamine market are Johnson & Johnson, Janssen Pharmaceuticals, Sage Therapeutics Inc., VistaGen Therapeutics Inc., Cerecor Inc., Celon Pharma S.A., Hikma Pharmaceuticals plc, Seqens Group, Arevipharma GmbH, Nortec Química S.A., Supriya Lifescience Ltd., Maithri Drugs Pvt. Ltd., SynZeal Research Pvt. Ltd., XWPharma Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Aurobindo Pharma Ltd., H. Lundbeck A/S, Otsuka Pharmaceutical Co. Ltd.

Access The Complete Esketamine Market Report:

https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report

Which Geographic Region Represents The Largest Esketamine Market Share?

North America was the largest region in the esketamine market in 2025. The regions covered in the esketamine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Esketamine Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp

Browse Through More Reports Similar to the Global Esketamine Market 2026, By The Business Research Company

Epinephrine Market Report 2026

https://www.thebusinessresearchcompany.com/report/epinephrine-global-market-report

Anti Infective Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market

Anticholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anticholinergic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Esketamine Market Grow Between 2026 And 2030?

The esketamine market size has seen a rapid increase in recent years. It is anticipated to expand from $1.51 billion in 2025 to $1.67 billion in 2026, at a compound annual growth rate (CAGR) of 10.8%. The historical growth trajectory can be attributed to several factors including unmet needs in major depressive disorder, the limitations inherent in traditional antidepressants, the successful obtainment of regulatory approvals for nasal esketamine, a heightened awareness surrounding mental health issues, and the broadening reach of specialty psychiatric clinics.

The esketamine market is anticipated to experience substantial expansion over the upcoming years. Its valuation is projected to reach $2.5 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.6%. Factors contributing to this growth during the forecast period include the rising incidence of treatment-resistant depression, the increasing need for quickly effective treatments, the broader availability of supervised outpatient administration, the development of mental health infrastructure, and ongoing investment in clinical research. Key trends for the forecast period involve a greater acceptance for treatment-resistant depression, wider use of nasal spray administration, increased application in urgent psychiatric settings, enhanced monitoring and regulated distribution, and expanding investigations into rapid-onset antidepressants.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp

Which Strong Drivers Are Impacting The Esketamine Market Growth?

The increasing prevalence of treatment-resistant depression (TRD) is projected to boost the growth of the esketamine market in the coming years. TRD refers to a form of depression that fails to improve after trying at least two different antidepressant medications at proper doses for a sufficient duration. The rise in TRD is attributed to the limited effectiveness of conventional antidepressants, which often leads to prolonged and recurrent depressive episodes. Esketamine aids TRD by employing a fast-acting mechanism that targets NMDA receptors, providing relief for patients who do not respond to traditional antidepressants. For instance, in September 2023, the National Institute of Mental Health (NIMH), a US-based federal agency, reported that approximately 30% of individuals with major depressive disorder in the U.S. were resistant to standard treatments in 2023. Hence, the increasing incidence of treatment-resistant depression is fueling the expansion of the esketamine market.

Which Segment Classifications Are Used In The Esketamine Market Segment Analysis?

The esketamine market covered in this report is segmented –

1) By Formulation Type: Nasal Spray, Injectable Form

2) By Indication: Treatment-Resistant Depression (TRD), Major Depressive Disorder with Suicidal Ideation or Behavior

3) By Patient Type: Adult Patients

4) By Treatment Setting: Hospital-Based Administration, Certified Specialty Clinics

5) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies

Subsegments:

1) By Nasal Spray: Single-Agent Esketamine Nasal Spray, Esketamine + Oral Antidepressant Combination Therapy

2) By Injectable Form: Intravenous (IV) Esketamine, Intramuscular (IM) Esketamine

Which Trends Are Influencing Demand In The Esketamine Market?

Major companies operating in the esketamine market are concentrating on developing advanced treatment solutions, such as monotherapy, to enhance depressive symptom relief beyond what placebo offers. Monotherapy refers to the use of a single drug or treatment to manage a disease or medical condition, rather than combining multiple therapies. For instance, in January 2025, Johnson & Johnson, a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved SPRAVATO (esketamine) as the first and only monotherapy for adults with treatment-resistant depression (TRD). Supported by clinical trials, the approval demonstrated that SPRAVATO could rapidly alleviate depressive symptoms, with significant improvements observed within 24 hours. This breakthrough provides a critical option for approximately 30% of individuals who do not respond to traditional antidepressants, eliminating the need for concurrent oral medications. While SPRAVATO has a favorable safety profile, it is administered under a Risk Evaluation and Mitigation Strategy (REMS) to address potential side effects. This milestone marks a significant advancement in TRD treatment, offering renewed hope for improved patient outcomes.

Which Firms Are Contributing To The Esketamine Market Ecosystem?

Major companies operating in the esketamine market are Johnson & Johnson, Janssen Pharmaceuticals, Sage Therapeutics Inc., VistaGen Therapeutics Inc., Cerecor Inc., Celon Pharma S.A., Hikma Pharmaceuticals plc, Seqens Group, Arevipharma GmbH, Nortec Química S.A., Supriya Lifescience Ltd., Maithri Drugs Pvt. Ltd., SynZeal Research Pvt. Ltd., XWPharma Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Aurobindo Pharma Ltd., H. Lundbeck A/S, Otsuka Pharmaceutical Co. Ltd.

Get The Full Esketamine Market Report:

https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report

Which Region Represents The Largest Share Of The Esketamine Market?

North America was the largest region in the esketamine market in 2025. The regions covered in the esketamine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Esketamine Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report

Browse Through More Reports Similar to the Global Esketamine Market 2026, By The Business Research Company

Epinephrine Market Report 2026

https://www.thebusinessresearchcompany.com/report/epinephrine-global-market-report

Anti Infective Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market

Anticholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anticholinergic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Esketamine Market Grow Between 2026 And 2030?

The esketamine market size has seen a rapid increase in recent years. It is anticipated to expand from $1.51 billion in 2025 to $1.67 billion in 2026, at a compound annual growth rate (CAGR) of 10.8%. The historical growth trajectory can be attributed to several factors including unmet needs in major depressive disorder, the limitations inherent in traditional antidepressants, the successful obtainment of regulatory approvals for nasal esketamine, a heightened awareness surrounding mental health issues, and the broadening reach of specialty psychiatric clinics.

The esketamine market is anticipated to experience substantial expansion over the upcoming years. Its valuation is projected to reach $2.5 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.6%. Factors contributing to this growth during the forecast period include the rising incidence of treatment-resistant depression, the increasing need for quickly effective treatments, the broader availability of supervised outpatient administration, the development of mental health infrastructure, and ongoing investment in clinical research. Key trends for the forecast period involve a greater acceptance for treatment-resistant depression, wider use of nasal spray administration, increased application in urgent psychiatric settings, enhanced monitoring and regulated distribution, and expanding investigations into rapid-onset antidepressants.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp

Which Strong Drivers Are Impacting The Esketamine Market Growth?

The increasing prevalence of treatment-resistant depression (TRD) is projected to boost the growth of the esketamine market in the coming years. TRD refers to a form of depression that fails to improve after trying at least two different antidepressant medications at proper doses for a sufficient duration. The rise in TRD is attributed to the limited effectiveness of conventional antidepressants, which often leads to prolonged and recurrent depressive episodes. Esketamine aids TRD by employing a fast-acting mechanism that targets NMDA receptors, providing relief for patients who do not respond to traditional antidepressants. For instance, in September 2023, the National Institute of Mental Health (NIMH), a US-based federal agency, reported that approximately 30% of individuals with major depressive disorder in the U.S. were resistant to standard treatments in 2023. Hence, the increasing incidence of treatment-resistant depression is fueling the expansion of the esketamine market.

Which Segment Classifications Are Used In The Esketamine Market Segment Analysis?

The esketamine market covered in this report is segmented –

1) By Formulation Type: Nasal Spray, Injectable Form

2) By Indication: Treatment-Resistant Depression (TRD), Major Depressive Disorder with Suicidal Ideation or Behavior

3) By Patient Type: Adult Patients

4) By Treatment Setting: Hospital-Based Administration, Certified Specialty Clinics

5) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies

Subsegments:

1) By Nasal Spray: Single-Agent Esketamine Nasal Spray, Esketamine + Oral Antidepressant Combination Therapy

2) By Injectable Form: Intravenous (IV) Esketamine, Intramuscular (IM) Esketamine

Which Trends Are Influencing Demand In The Esketamine Market?

Major companies operating in the esketamine market are concentrating on developing advanced treatment solutions, such as monotherapy, to enhance depressive symptom relief beyond what placebo offers. Monotherapy refers to the use of a single drug or treatment to manage a disease or medical condition, rather than combining multiple therapies. For instance, in January 2025, Johnson & Johnson, a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved SPRAVATO (esketamine) as the first and only monotherapy for adults with treatment-resistant depression (TRD). Supported by clinical trials, the approval demonstrated that SPRAVATO could rapidly alleviate depressive symptoms, with significant improvements observed within 24 hours. This breakthrough provides a critical option for approximately 30% of individuals who do not respond to traditional antidepressants, eliminating the need for concurrent oral medications. While SPRAVATO has a favorable safety profile, it is administered under a Risk Evaluation and Mitigation Strategy (REMS) to address potential side effects. This milestone marks a significant advancement in TRD treatment, offering renewed hope for improved patient outcomes.

Which Firms Are Contributing To The Esketamine Market Ecosystem?

Major companies operating in the esketamine market are Johnson & Johnson, Janssen Pharmaceuticals, Sage Therapeutics Inc., VistaGen Therapeutics Inc., Cerecor Inc., Celon Pharma S.A., Hikma Pharmaceuticals plc, Seqens Group, Arevipharma GmbH, Nortec Química S.A., Supriya Lifescience Ltd., Maithri Drugs Pvt. Ltd., SynZeal Research Pvt. Ltd., XWPharma Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Aurobindo Pharma Ltd., H. Lundbeck A/S, Otsuka Pharmaceutical Co. Ltd.

Get The Full Esketamine Market Report:

https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report

Which Region Represents The Largest Share Of The Esketamine Market?

North America was the largest region in the esketamine market in 2025. The regions covered in the esketamine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Esketamine Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report

Browse Through More Reports Similar to the Global Esketamine Market 2026, By The Business Research Company

Epinephrine Market Report 2026

https://www.thebusinessresearchcompany.com/report/epinephrine-global-market-report

Anti Infective Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market

Anticholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anticholinergic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Esketamine Market Grow Between 2026 And 2030?

The esketamine market size has seen a rapid increase in recent years. It is anticipated to expand from $1.51 billion in 2025 to $1.67 billion in 2026, at a compound annual growth rate (CAGR) of 10.8%. The historical growth trajectory can be attributed to several factors including unmet needs in major depressive disorder, the limitations inherent in traditional antidepressants, the successful obtainment of regulatory approvals for nasal esketamine, a heightened awareness surrounding mental health issues, and the broadening reach of specialty psychiatric clinics.

The esketamine market is anticipated to experience substantial expansion over the upcoming years. Its valuation is projected to reach $2.5 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.6%. Factors contributing to this growth during the forecast period include the rising incidence of treatment-resistant depression, the increasing need for quickly effective treatments, the broader availability of supervised outpatient administration, the development of mental health infrastructure, and ongoing investment in clinical research. Key trends for the forecast period involve a greater acceptance for treatment-resistant depression, wider use of nasal spray administration, increased application in urgent psychiatric settings, enhanced monitoring and regulated distribution, and expanding investigations into rapid-onset antidepressants.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp

Which Strong Drivers Are Impacting The Esketamine Market Growth?

The increasing prevalence of treatment-resistant depression (TRD) is projected to boost the growth of the esketamine market in the coming years. TRD refers to a form of depression that fails to improve after trying at least two different antidepressant medications at proper doses for a sufficient duration. The rise in TRD is attributed to the limited effectiveness of conventional antidepressants, which often leads to prolonged and recurrent depressive episodes. Esketamine aids TRD by employing a fast-acting mechanism that targets NMDA receptors, providing relief for patients who do not respond to traditional antidepressants. For instance, in September 2023, the National Institute of Mental Health (NIMH), a US-based federal agency, reported that approximately 30% of individuals with major depressive disorder in the U.S. were resistant to standard treatments in 2023. Hence, the increasing incidence of treatment-resistant depression is fueling the expansion of the esketamine market.

Which Segment Classifications Are Used In The Esketamine Market Segment Analysis?

The esketamine market covered in this report is segmented –

1) By Formulation Type: Nasal Spray, Injectable Form

2) By Indication: Treatment-Resistant Depression (TRD), Major Depressive Disorder with Suicidal Ideation or Behavior

3) By Patient Type: Adult Patients

4) By Treatment Setting: Hospital-Based Administration, Certified Specialty Clinics

5) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies

Subsegments:

1) By Nasal Spray: Single-Agent Esketamine Nasal Spray, Esketamine + Oral Antidepressant Combination Therapy

2) By Injectable Form: Intravenous (IV) Esketamine, Intramuscular (IM) Esketamine

Which Trends Are Influencing Demand In The Esketamine Market?

Major companies operating in the esketamine market are concentrating on developing advanced treatment solutions, such as monotherapy, to enhance depressive symptom relief beyond what placebo offers. Monotherapy refers to the use of a single drug or treatment to manage a disease or medical condition, rather than combining multiple therapies. For instance, in January 2025, Johnson & Johnson, a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved SPRAVATO (esketamine) as the first and only monotherapy for adults with treatment-resistant depression (TRD). Supported by clinical trials, the approval demonstrated that SPRAVATO could rapidly alleviate depressive symptoms, with significant improvements observed within 24 hours. This breakthrough provides a critical option for approximately 30% of individuals who do not respond to traditional antidepressants, eliminating the need for concurrent oral medications. While SPRAVATO has a favorable safety profile, it is administered under a Risk Evaluation and Mitigation Strategy (REMS) to address potential side effects. This milestone marks a significant advancement in TRD treatment, offering renewed hope for improved patient outcomes.

Which Firms Are Contributing To The Esketamine Market Ecosystem?

Major companies operating in the esketamine market are Johnson & Johnson, Janssen Pharmaceuticals, Sage Therapeutics Inc., VistaGen Therapeutics Inc., Cerecor Inc., Celon Pharma S.A., Hikma Pharmaceuticals plc, Seqens Group, Arevipharma GmbH, Nortec Química S.A., Supriya Lifescience Ltd., Maithri Drugs Pvt. Ltd., SynZeal Research Pvt. Ltd., XWPharma Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Aurobindo Pharma Ltd., H. Lundbeck A/S, Otsuka Pharmaceutical Co. Ltd.

Get The Full Esketamine Market Report:

https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report

Which Region Represents The Largest Share Of The Esketamine Market?

North America was the largest region in the esketamine market in 2025. The regions covered in the esketamine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Esketamine Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report

Browse Through More Reports Similar to the Global Esketamine Market 2026, By The Business Research Company

Epinephrine Market Report 2026

https://www.thebusinessresearchcompany.com/report/epinephrine-global-market-report

Anti Infective Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market

Anticholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anticholinergic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Esketamine Market Over The Period 2026–2030?

The esketamine market has experienced swift expansion in recent years. It is forecast to rise from $1.51 billion in 2025 to $1.67 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.8%. The historical increase in market size is due to unaddressed requirements in major depressive disorder, the constraints of conventional antidepressants, regulatory clearances for nasal esketamine, a growing understanding of mental health, and the establishment of specialty psychiatric clinics.

The esketamine market is projected to experience substantial expansion over the upcoming years. By 2030, its valuation is anticipated to reach $2.5 billion, demonstrating a compound annual growth rate (CAGR) of 10.6%. This projected increase during the forecast period stems from factors such as the rising incidence of treatment-resistant depression, a heightened need for rapidly effective treatments, the broader availability of supervised outpatient administration, improvements in mental health infrastructure, and ongoing investment in clinical research. Key developments expected throughout this period involve the greater acceptance for treatment-resistant depression, the wider use of nasal spray delivery methods, increased application in acute psychiatric care environments, enhanced oversight and regulated distribution, and intensified investigation into swift-acting antidepressants.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp

Which Economic Or Industry Drivers Are Impacting The Esketamine Market?

The increasing prevalence of treatment-resistant depression (TRD) is anticipated to propel the growth of the esketamine market in the coming years. Treatment-resistant depression (TRD) refers to depression that does not show improvement after attempting at least two different antidepressant medications at appropriate doses for a sufficient duration. The rise in treatment-resistant depression (TRD) is due to the limited effectiveness of conventional antidepressants, leading to prolonged and recurring depressive episodes. Esketamine aids treatment-resistant depression (TRD) by offering a fast-acting mechanism that targets NMDA receptors, providing relief for patients who do not respond to traditional antidepressants. For instance, in September 2023, the National Institute of Mental Health (NIMH), a US-based federal agency, reported that, in 2023, about 30% of individuals with major depressive disorder in the U.S. are resistant to standard treatments. Therefore, the rising incidence of treatment-resistant depression is driving the growth of the esketamine market.

How Is The Esketamine Market Divided Into Its Major Segments?

The esketamine market covered in this report is segmented –

1) By Formulation Type: Nasal Spray, Injectable Form

2) By Indication: Treatment-Resistant Depression (TRD), Major Depressive Disorder with Suicidal Ideation or Behavior

3) By Patient Type: Adult Patients

4) By Treatment Setting: Hospital-Based Administration, Certified Specialty Clinics

5) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies

Subsegments:

1) By Nasal Spray: Single-Agent Esketamine Nasal Spray, Esketamine + Oral Antidepressant Combination Therapy

2) By Injectable Form: Intravenous (IV) Esketamine, Intramuscular (IM) Esketamine

How Are Trends Transforming The Esketamine Market Landscape?

Leading companies in the esketamine market are concentrating on developing advanced therapeutic solutions, such as monotherapy, to boost the relief of depressive symptoms beyond what a placebo can offer. Monotherapy refers to the application of a single drug or treatment for managing a disease or medical condition, rather than integrating multiple therapies. For example, in January 2025, Johnson & Johnson, a US-based pharmaceutical entity, disclosed that the U.S. Food and Drug Administration (FDA) had granted approval for SPRAVATO (esketamine) as the initial and only monotherapy for adults experiencing treatment-resistant depression (TRD). Endorsed by clinical trials, this approval demonstrated SPRAVATO’s capacity to swiftly ease depressive symptoms, with considerable improvements observed within 24 hours. This innovation presents a crucial choice for approximately 30% of individuals who do not respond to conventional antidepressants, thereby eliminating the necessity for concurrent oral medications. While SPRAVATO exhibits a favorable safety profile, it is administered within a Risk Evaluation and Mitigation Strategy (REMS) to manage potential adverse reactions. This landmark signifies a substantial progression in TRD treatment, providing renewed optimism for better patient outcomes.

Who Are The Prominent Organizations Shaping The Esketamine Market?

Major companies operating in the esketamine market are Johnson & Johnson, Janssen Pharmaceuticals, Sage Therapeutics Inc., VistaGen Therapeutics Inc., Cerecor Inc., Celon Pharma S.A., Hikma Pharmaceuticals plc, Seqens Group, Arevipharma GmbH, Nortec Química S.A., Supriya Lifescience Ltd., Maithri Drugs Pvt. Ltd., SynZeal Research Pvt. Ltd., XWPharma Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Aurobindo Pharma Ltd., H. Lundbeck A/S, Otsuka Pharmaceutical Co. Ltd.

Read the full esketamine market report here:

https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report

What Are The Top-Performing Regions Within The Esketamine Market?

North America was the largest region in the esketamine market in 2025. The regions covered in the esketamine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Esketamine Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23393&type=smp

Browse Through More Reports Similar to the Global Esketamine Market 2026, By The Business Research Company

Epinephrine Market Report 2026

https://www.thebusinessresearchcompany.com/report/epinephrine-global-market-report

Anti Infective Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market

Anticholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anticholinergic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the esketamine market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Esketamine Market’s size between 2026 and 2030?

The esketamine market’s valuation has experienced substantial growth in recent years. It is projected to increase from $1.51 billion in 2025 to $1.67 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.8%. The expansion observed in the historic period is primarily due to unmet needs in major depressive disorder, the limitations of traditional antidepressants, regulatory approvals for nasal esketamine, growing mental health awareness, and the proliferation of specialty psychiatric clinics.

The esketamine market is anticipated to experience substantial growth in the upcoming years, with projections indicating it will reach $2.5 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.6%. This expansion throughout the forecast period can be attributed to the increasing prevalence of treatment-resistant depression, a rising demand for fast-acting therapies, the wider availability of supervised outpatient administration, the development of mental health infrastructure, and continuous investment in clinical research. Major trends expected during this period encompass the growing acceptance for treatment-resistant depression, the expansion of nasal spray administration methods, increased utilization in acute psychiatric care settings, enhanced monitoring and controlled distribution practices, and ongoing research into rapid-acting antidepressants.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp

Which Drivers Are Shaping Strategic Decisions In The Esketamine Market?

The increasing prevalence of treatment-resistant depression (TRD) is anticipated to propel the growth of the esketamine market in the coming years. Treatment-resistant depression (TRD) is defined as depression that does not improve after attempting at least two different antidepressant medications at proper doses for a sufficient duration. The rise in treatment-resistant depression (TRD) is attributed to the limited efficacy of conventional antidepressants, which results in prolonged and recurrent depressive episodes. Esketamine helps treatment-resistant depression (TRD) by providing a fast-acting mechanism that targets the NMDA receptors, offering relief for patients who do not respond to traditional antidepressants. For instance, in September 2023, the National Institute of Mental Health (NIMH), a US-based federal agency, reported that, in 2023, about 30% of individuals with major depressive disorder in the U.S. are resistant to standard treatments. Therefore, the rising incidence of treatment-resistant depression is driving the growth of the esketamine market.

What Segment Classifications Make Up The Esketamine Market?

The esketamine market covered in this report is segmented –

1) By Formulation Type: Nasal Spray, Injectable Form

2) By Indication: Treatment-Resistant Depression (TRD), Major Depressive Disorder with Suicidal Ideation or Behavior

3) By Patient Type: Adult Patients

4) By Treatment Setting: Hospital-Based Administration, Certified Specialty Clinics

5) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies

Subsegments:

1) By Nasal Spray: Single-Agent Esketamine Nasal Spray, Esketamine + Oral Antidepressant Combination Therapy

2) By Injectable Form: Intravenous (IV) Esketamine, Intramuscular (IM) Esketamine

Which Trends Are Guiding The Evolution Of The Esketamine Market?

Leading companies in the esketamine market are focusing on developing advanced therapeutic solutions, such as monotherapy, to enhance relief from depressive symptoms beyond what a placebo offers. Monotherapy refers to using a single drug or treatment to manage a disease or medical condition, rather than combining multiple therapies. For instance, in January 2025, Johnson & Johnson, a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved SPRAVATO (esketamine) as the first and only monotherapy for adults with treatment-resistant depression (TRD). Supported by clinical trials, this approval demonstrated that SPRAVATO could rapidly alleviate depressive symptoms, with significant improvements observed within 24 hours. This breakthrough provides a critical option for approximately 30% of individuals who do not respond to traditional antidepressants, eliminating the need for concurrent oral medications. While SPRAVATO has a favorable safety profile, it is administered under a Risk Evaluation and Mitigation Strategy (REMS) to address potential side effects. This milestone marks a significant advancement in TRD treatment, offering renewed hope for improved patient outcomes.

Which Leading Companies Dominate The Esketamine Market Share?

Major companies operating in the esketamine market are Johnson & Johnson, Janssen Pharmaceuticals, Sage Therapeutics Inc., VistaGen Therapeutics Inc., Cerecor Inc., Celon Pharma S.A., Hikma Pharmaceuticals plc, Seqens Group, Arevipharma GmbH, Nortec Química S.A., Supriya Lifescience Ltd., Maithri Drugs Pvt. Ltd., SynZeal Research Pvt. Ltd., XWPharma Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Aurobindo Pharma Ltd., H. Lundbeck A/S, Otsuka Pharmaceutical Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report

How Does The Esketamine Market Perform Across Major Global Regions?

North America was the largest region in the esketamine market in 2025. The regions covered in the esketamine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Esketamine Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23393&type=smp

Browse Through More Reports Similar to the Global Esketamine Market 2026, By The Business Research Company

Epinephrine Market Report 2026

https://www.thebusinessresearchcompany.com/report/epinephrine-global-market-report

Anti Infective Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market

Anticholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anticholinergic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the vitamin tonics market from 2025–2034 with trusted insights from The Business Research Company

What Is The Predicted Size Of The Vitamin Tonics Industry By 2029?

The esketamine market size has experienced robust growth in recent years. This market is projected to expand from $1.37 billion in 2024 to $1.51 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 9.9%. Historically, this expansion can be linked to factors such as a rise in patient numbers, the increasing global prevalence of mental health challenges, enhanced awareness regarding the disease state, a growing need for innovative therapeutic choices, and positive regulatory clearances.

The esketamine market is set to experience substantial expansion in the coming years, with its valuation expected to reach $2.26 billion by 2029, progressing at a compound annual growth rate (CAGR) of 10.7%. This anticipated growth during the forecast period stems from the rising occurrence of treatment-resistant depression, heightened investment in research and development efforts, a growing need for smart healthcare infrastructure, the increasing adoption of telehealth services, and the broader acceptance of esketamine as an effective therapeutic option. Significant trends for the forecast duration involve alliances between biotech firms and mental health organizations, the application of robotics in healthcare, customized medicine strategies, the use of sensor-based devices, and the development of potential combination therapies.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp

What Major Drivers Are Impacting The Vitamin Tonics Market?

The growing occurrence of treatment-resistant depression (TRD) is anticipated to fuel the expansion of the esketamine market in the foreseeable future. Treatment-resistant depression (TRD) is defined as a form of depression that does not respond adequately after individuals have attempted at least two distinct antidepressant treatments, administered at appropriate dosages and for an adequate period. The rise in TRD cases stems from the restricted effectiveness of traditional antidepressants, which often results in extended and recurring episodes of depression. Esketamine addresses treatment-resistant depression (TRD) by utilizing a rapid-onset mechanism that specifically targets the NMDA receptors, thus providing symptomatic relief for patients unresponsive to conventional antidepressant therapies. For example, in September 2023, the National Institute of Mental Health (NIMH), a US-based federal agency, reported that roughly 30% of individuals diagnosed with major depressive disorder in the U.S. in 2023 exhibit resistance to standard therapeutic approaches. Consequently, the increasing incidence of treatment-resistant depression is a key factor propelling the expansion of the esketamine market.

Which Segment Categories Are Driving Maximum Growth In The Vitamin Tonics Market?

The esketamine market covered in this report is segmented –

1) By Type: Oral Medications, Injection, Nasal Spray, Other Types

2) By Indication: Major Depressive Disorder, Chronic Pain, Post-Traumatic Stress Disorder, Anxiety Disorders

3) By Patient Type: Adult Patients, Pediatric Patients, Geriatric Patients

4) By Application: General Anesthetic, Treatment-Resistant Depression

5) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

Subsegments:

1) By Oral Medications: Immediate-Release Tablets, Extended-Release Tablets, Sublingual Tablets

2) By Injection: Intravenous Injection, Intramuscular Injection, Subcutaneous Injection

3) By Nasal Spray: Prescription Nasal Spray, Over-The-Counter Nasal Spray, Combination Therapy Nasal Spray

4) By Other Types: Plasmapheresis, Intravenous Immunoglobulin (IVIG) Therapy, Stem Cell Therapy

Which Long-Term Trends Will Play A Crucial Role In The Vitamin Tonics Market?

Leading companies in the esketamine market are concentrating on developing advanced treatment solutions, such as monotherapy, to improve depressive symptom relief beyond what a placebo offers. Monotherapy refers to utilizing a single drug or treatment to manage a disease or medical condition, instead of combining multiple therapies. For instance, in January 2025, Johnson & Johnson, a US-based pharmaceutical company, announced the U.S. Food and Drug Administration (FDA) had approved SPRAVATO (esketamine) as the first and only monotherapy for adults with treatment-resistant depression (TRD). Supported by clinical trials, this approval demonstrated that SPRAVATO could rapidly alleviate depressive symptoms, with significant improvements observed within 24 hours. This breakthrough offers a crucial option for approximately 30% of individuals who do not respond to traditional antidepressants, eliminating the need for concurrent oral medications. While SPRAVATO has a favorable safety profile, it is administered under a Risk Evaluation and Mitigation Strategy (REMS) to address potential side effects. This milestone represents a significant advancement in TRD treatment, providing renewed hope for improved patient outcomes.

Who Are The Dominant Players In The Vitamin Tonics Market Today?

Major companies operating in the esketamine market are Cigna Corporation, Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sigma-Aldrich Corporation, Horizon Therapeutics plc, Hikma Pharmaceuticals plc, Cerecor Inc., Celon Pharma S.A., Nortec Química S.A., XWPharma Ltd., Seqens Group, SynZeal Research Pvt. Ltd., Arevipharma GmbH, Sage Therapeutics Inc., Supriya Lifescience Ltd., Clexio Biosciences Ltd., Maithri Drugs Pvt. Ltd., VistaGen Therapeutics Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report

Which Region Is At The Forefront Of Innovation In The Vitamin Tonics Market?

North America was the largest region in the esketamine market in 2024. The regions covered in the esketamine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=23393&type=smp

Browse Through More Reports Similar to the Global Vitamin Tonics Market 2025, By The Business Research Company

Inhalation And Nasal Spray Generic Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/inhalation-and-nasal-spray-generic-drugs-global-market-report

Antidepressant Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antidepressant-global-market-report

Postpartum Depression Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/postpartum-depression-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The Esketamine Market Between 2025 And 2029?

The esketamine market has experienced significant expansion in recent years. Its value is projected to rise from $1.37 billion in 2024 to $1.51 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 9.9%. This past growth can be attributed to several factors including an increased patient count, the rising global prevalence of mental health disorders, better awareness of the disease state, a growing need for new therapeutic solutions, and supportive regulatory approvals.

The esketamine market is set to experience significant expansion in the upcoming years. Its value is projected to reach $2.26 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.7%. This growth over the forecast period is driven by several factors, including the increasing occurrence of treatment-resistant depression, heightened investment in research and development programs, a rising demand for smart healthcare infrastructure, the expanding trend of telehealth services, and the growing acceptance of esketamine as an effective therapeutic option. Notable trends anticipated during this period encompass partnerships between biotechnology firms and mental health organizations, the application of robotics in healthcare, personalized medicine strategies, the use of sensor-based devices, and the potential for combination therapies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp

Which Drivers Are Impacting The Esketamine Market?

The increasing occurrence of treatment-resistant depression (TRD) is anticipated to propel the growth of the esketamine market in the coming years. Treatment-resistant depression (TRD) describes depression that does not improve after trying at least two different antidepressant medications at proper doses for a sufficient duration. The rise in treatment-resistant depression (TRD) is due to the limited effectiveness of conventional antidepressants, leading to prolonged and recurring depressive episodes. Esketamine helps treatment-resistant depression (TRD) by offering a fast-acting mechanism that targets the NMDA receptors, providing relief for patients who do not respond to traditional antidepressants. For instance, in September 2023, the National Institute of Mental Health (NIMH), a US-based federal agency, reported that, in 2023, about 30% of individuals with major depressive disorder in the U.S. are resistant to standard treatments. Therefore, the rising incidence of treatment-resistant depression is driving the growth of the esketamine market.

How Is The Esketamine Market Classified Into Different Segments?

The esketamine market covered in this report is segmented –

1) By Type: Oral Medications, Injection, Nasal Spray, Other Types

2) By Indication: Major Depressive Disorder, Chronic Pain, Post-Traumatic Stress Disorder, Anxiety Disorders

3) By Patient Type: Adult Patients, Pediatric Patients, Geriatric Patients

4) By Application: General Anesthetic, Treatment-Resistant Depression

5) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

Subsegments:

1) By Oral Medications: Immediate-Release Tablets, Extended-Release Tablets, Sublingual Tablets

2) By Injection: Intravenous Injection, Intramuscular Injection, Subcutaneous Injection

3) By Nasal Spray: Prescription Nasal Spray, Over-The-Counter Nasal Spray, Combination Therapy Nasal Spray

4) By Other Types: Plasmapheresis, Intravenous Immunoglobulin (IVIG) Therapy, Stem Cell Therapy

Which Ongoing Trends Are Expected To Shape The Esketamine Market Outlook?

Leading companies in the esketamine market are prioritizing the creation of advanced treatment solutions, such as monotherapy, to offer enhanced relief from depressive symptoms beyond what a placebo provides. Monotherapy signifies the application of a single drug or treatment to manage a disease or medical condition, instead of utilizing multiple therapies in combination. For example, in January 2025, Johnson & Johnson, a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had given its approval to SPRAVATO (esketamine) as the initial and sole monotherapy for adults diagnosed with treatment-resistant depression (TRD). Supported by clinical trials, this approval demonstrated SPRAVATO’s capacity to quickly lessen depressive symptoms, with considerable improvements noted within 24 hours. This innovation offers a crucial alternative for approximately 30% of individuals who do not respond to conventional antidepressants, thereby removing the necessity for concurrent oral medications. While SPRAVATO maintains a favorable safety profile, it is administered under a Risk Evaluation and Mitigation Strategy (REMS) to manage potential side effects. This accomplishment represents a significant progression in TRD treatment, instilling renewed hope for improved patient outcomes.

Who Are The Core Companies Influencing The Esketamine Market Landscape?

Major companies operating in the esketamine market are Cigna Corporation, Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sigma-Aldrich Corporation, Horizon Therapeutics plc, Hikma Pharmaceuticals plc, Cerecor Inc., Celon Pharma S.A., Nortec Química S.A., XWPharma Ltd., Seqens Group, SynZeal Research Pvt. Ltd., Arevipharma GmbH, Sage Therapeutics Inc., Supriya Lifescience Ltd., Clexio Biosciences Ltd., Maithri Drugs Pvt. Ltd., VistaGen Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report

What Are The Key Regional Factors Influencing The Esketamine Market Growth?

North America was the largest region in the esketamine market in 2024. The regions covered in the esketamine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Esketamine Market Report:

https://www.thebusinessresearchcompany.com/customise?id=23393&type=smp

Browse Through More Reports Similar to the Global Esketamine Market 2025, By The Business Research Company

Inhalation And Nasal Spray Generic Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/inhalation-and-nasal-spray-generic-drugs-global-market-report

Antidepressant Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antidepressant-global-market-report

Postpartum Depression Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/postpartum-depression-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model